Brief: Aardvark Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
14/05/2025 22:21
May 14 (Reuters) - Aardvark Therapeutics Inc AARD.O: AARDVARK THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS AARDVARK THERAPEUTICS INC - AS OF MARCH 31, 2025, AARDVARK HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF $151.3 MILLION Source text: ID:nGNXb9Z5BT Further company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aardvark Therapeutics
See all newsBrief: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., Mba, To Its Board Of Directors
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark